Amphotericin B
- Atc Codes:A01AB04#A07AA07#G01AA03#J02AA01
- CAS Codes:1397-89-3
- PHARMGKB ID:1397-89-3
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Denmark: Fungizone; Finland: Fungizone; France: Fungizone; Germany: Fungizone; Hungary: Fungizone; Ireland: Fungizone; Italy: Fungizone; Netherlands: Fungizone; Portugal: Fungizone; Romania: Fungizone; Spain: Fungizona; Sweden: Fungizone; UK: Fungizone.
North America
Canada: Fungizone; USA: Fungizone.
Latin America
Brazil: Fungizon.
Drug combinations
Amphotericin B and Tetracycline
Chemistry
Amphotericin B: C~47~H~73~NO~17~. Mw: 924.08. [1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*,18S*,19E,21E,23E,25E,27E,29E,31E,33R*,35S*,36R*,37S*)]-33-[(3-Amino-3,6-dideoxy-β-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid. CAS-1397-89-3.
Pharmacologic Category
Antifungals; Polyenes. (ATC-Code: A01AB04; A07AA07; G01AA03; J02AA01).
Mechanism of action
Binds to ergosterol, causing cell death in susceptible fungi. Oxidation-dependent stimulation of macrophages.
Therapeutic use
Treatment of severe systemic and central nervous system infections caused by susceptible fungi such as Candida species, Histoplasma capsulatum, Cryptococcus neoformans, Aspergillus species, Blastomyces dermatitidis, Torulopsis glabrata, and Coccidioides immitis. Fungal peritonitis. Irrigant for bladder fungal infections. Used in fungal infection in bone marrow transplantation, amebic meningoencephalitis, ocular aspergillosis, candidal cystitis, chemoprophylaxis, immunocompromised patients at risk of aspergillosis, refractory meningitis, and coccidioidal arthritis.
Pregnancy and lactiation implications
Contraindicated during lactation (excretion in breast milk unknown).
Unlabeled use
Contraindications
Hypersensitivity to amphotericin or any component of the formulation.
Warnings and precautions
Possibility of anaphylactic reaction. Acute infusion reactions may occur (more common with the first few doses and generally diminishing with subsequent doses). Use with caution in renal impairment. Avoid use with other nephrotoxic drugs. Pulmonary reactions may occur in neutropenic patients receiving leukocyte transfusions.